Picture EBD Group Global Partnering Four Events One Price 650x80
Document › Details

GenSight Biologics S.A.. (6/23/17). "Press Release: GenSight Biologics Successfully Raises €22.5 Million from Leading Investors in the US and Europe [Not for distribution in Canada, Australia and Japan]". Paris.

Organisations Organisation GenSight Biologics S.A. (Euronext: SIGHT)
  Group OTHER
Products Product lenadogene nolparvovec (GS010)
  Product 2 investment banking
Index term Index term GenSight Biologics–SEVERAL: investment, 201706 capital increase €22.5m €6/share with Europ + US institutional investors
Persons Person Gidoin, Thomas (GenSight Biologics 201507 CFO)
  Person 2 Janic, Marion (RooneyPartners 201702 Partner joined 2008)

Record changed: 2017-06-28


Picture BIO Deutschland German Corona Special 2021 Digital 650x80px

More documents for GenSight Biologics S.A. (Euronext: SIGHT)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Berlin Partner Network in German Capital Region 650x80px

» top